Table 1 Characterisation of MB original patient samples and their derived cell lines
From: Overcoming multiple drug resistance mechanisms in medulloblastoma
Name | Tumour | Â | Cell lines | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Histology | IHC MB subtype marker | CTNNB1 mutated | IHC ABCB1 % | IHC MGMT | MB subtype | Subtype QRTPCR | MYC status | CTNNB1 mutated | MB subtype |
MED 1 | LC/A | KCNA1 | No | 11.2 | - | Group 4 | KCNA1 positive | MYCN Amplified | No | Group 4 |
MED 3 | Classical | Moderate NPR3 | No | 0 | + | Group 3 | NPR3 positive | Normal | No | Group 3 |
MED4 | LC/A | NPR3 | No | 1.9 | + | Group 3 | NPR3 positive | MYCN gain | No | Group 3 |
MED4R | LC/A | NPR3 | No | 4.5 | + | Group 3 | NPR3 positive | MYCN gain | No | Group 3 |
MED5R | LC/A | β-catenin | Yes | 6.2 | + | WNT* | NPR3 positive | Normal | Yes | WNT |
MED6 | Classical | β-catenin | Yes | 1.2 | + | WNT* | NPR3 positive | Normal | No | Group 3 |
UW228-3 | Classical | NA | NA | NA | NA | Group 3 | NPR3 positive | MYCC gain | No | Group 3 |
DAOY | Desmoplastic | NA | NA | NA | NA | SHH? | None | Normal | No | SHH[62]** |